KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Leases: 2013-2024

Historic Leases for Regeneron Pharmaceuticals (REGN) over the last 1 years, with Dec 2024 value amounting to $591.2 million.

  • Regeneron Pharmaceuticals' Leases fell 2.39% to $591.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $591.2 million, marking a year-over-year decrease of 2.39%. This contributed to the annual value of $591.2 million for FY2024, which is 2.39% down from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Leases stood at $591.2 million for Q4 2024, which was down 2.39% from $605.7 million recorded in Q4 2023.
  • Regeneron Pharmaceuticals' 5-year Leases high stood at $645.7 million for Q4 2020, and its period low was $591.2 million during Q4 2024.
  • For the 3-year period, Regeneron Pharmaceuticals' Leases averaged around $605.7 million, with its median value being $605.7 million (2023).
  • Data for Regeneron Pharmaceuticals' Leases shows a maximum YoY declined of 2.39% (in 2024) over the last 5 years.
  • Regeneron Pharmaceuticals' Leases (Quarterly) stood at $645.7 million in 2020, then fell by 2.23% to $631.3 million in 2021, then decreased by 1.74% to $620.3 million in 2022, then fell by 2.35% to $605.7 million in 2023, then dropped by 2.39% to $591.2 million in 2024.
  • Its Leases stands at $591.2 million for Q4 2024, versus $605.7 million for Q4 2023 and $620.3 million for Q4 2022.